Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43977   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-002979-26
    Sponsor's Protocol Code Number:D419JC00001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Restarted
    Date on which this record was first entered in the EudraCT database:2018-04-09
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2017-002979-26
    A.3Full title of the trial
    A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non Muscle Invasive Bladder Cancer Patients (POTOMAC)
    Ensayo mundial fase III, aleatorizado, abierto, multicéntrico de Durvalumab y el Bacilo de Calmette-Guerin (BCG) administrados como terapia combinada en comparación con BCG en monoterapia, en pacientes con cáncer de vejiga no músculo invasivo de alto riesgo sin tratamiento previo con BCG (POTOMAC)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Study to evaluate the efficacy and safety of Durvalumab (MEDI4736) in combination with intravesical BCG for the treatment of patients diagnosed with early stage bladder cancer (non-muscle invasive) compare to the standard therapy of intravesical BCG alone.
    Ensayo para evaluar la eficacia y seguridad de durvalumab (MEDI4736) en combinación con BCG intravesical para el tratamiento de pacientes diagnosticados en estadíos tempranos de cáncer de vejiga (no músculo invasivo) comparado con el tratamiento de BCG intravesical en monoterapia.
    A.3.2Name or abbreviated title of the trial where available
    POTOMAC
    POTOMAC
    A.4.1Sponsor's protocol code numberD419JC00001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAstraZeneca AB
    B.1.3.4CountrySweden
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAstraZeneca AB
    B.4.2CountrySweden
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAstraZeneca Farmacéutica Spain, S.A.
    B.5.2Functional name of contact pointUnidad de Investigación Clínica
    B.5.3 Address:
    B.5.3.1Street AddressC/ Serrano Galvache, 56; Parque Norte, Edificio Álamo
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28033
    B.5.3.4CountrySpain
    B.5.4Telephone number003491900200444
    B.5.6E-mailinformacionEECC-Spain@astrazeneca.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namedurvalumab
    D.3.2Product code MEDI4736
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNdurvalumab
    D.3.9.1CAS number 1428935-60-7
    D.3.9.2Current sponsor codeMEDI4736
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBCG (Bacillus Calmette Guerrin)
    D.3.2Product code L03AX03
    D.3.4Pharmaceutical form Intravesical solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravesical use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Non-muscle invasive bladder cancer
    Cáncer de vejiga no músculo invasivo
    E.1.1.1Medical condition in easily understood language
    Bladder Cancer in early stages/ Stage 0/1 or cancer in situ
    Cáncer de vejiga en estadíos tempranos/ Estadío 0/1 o cáncer "in situ"
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10005008
    E.1.2Term Bladder cancer stage I, with cancer in situ
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To assess the efficacy of durvalumab + BCG combination therapy compared to BCG alone in terms of Disease Free Survival (DFS).
    Evaluar la eficacia del tratamiento combinado con durvalumab + BCG en comparación con BCG en monoterapia en términos de Supervivencia sin enfermedad (SSE)
    E.2.2Secondary objectives of the trial
    To assess the efficacy of the combination therapy (Durvalumab plus BCG) compared to SoC in terms of disease free at 24 months (DFS24), overall survival at 5 years (OS5), any disease-free survival (aDFS), time to muscle-invasive bladder cancer or metastatic disease, time to cystectomy and time to development of upper track urothelial carcinoma
    To assess disease-related symptoms and HRQoL in patients treated with durvalumab plus BCG combination therapy compared to SoC using EORTC QLQ-C30 and EORTC QLQ NMIBC24
    Tolerability using patient-reported PRO CTCAE symptoms
    To assess PK of durvalumab and Immunogenicity of durvalumab
    Evaluar la eficacia del tratamiento combinado (durvalumab + BCG) en comparación con la terapia estándar de tratamiento (SoC) en términos de 24 meses libres de enfermedad (SLE24), supervivencia global a los 5 años (SG5), toda supervivencia sin enfermedad (aSSE), el tiempo transcurrido hasta la aparición de cáncer de vejiga músculo no invasivo o metástasis, tiempo transcurrido hasta la cistectomía y el tiempo transcurrido hasta la aparición de carcinoma urotelial de las vías superiores.
    Para evaluar los síntomas relacionados con la enfermadad y CdVRS en pacientes tratados con la combinación de durvalumab+BCG comparado con SoC utilizando QLQ-LC30 de la EORTC y QLQ-NMIBC24 de la EORTC.
    Tolerabilidad utilizada por los informes notificados por los pacientes de los síntomas PRO-CTCAE.
    Evaluar la farmacocinética del durvalumab y la inmunogenicidad de durvalumab.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    -BCG-naïve (patients who have not received prior intravesical BCG or who previously received but stopped BCG more than 3 years before study entry are eligible).
    -Local histological confirmation (based on pathology report) of high-risk transitional cell carcinoma of the urothelium of the urinary bladder confined to the mucosa or submucosa. A high risk tumor is defined as one of the following:
     T1 tumor
     High grade/G3 tumor
     CIS
     Multiple and recurrent and large (with diameter of largest evaluable node ≥3 cm) tumors (all conditions must be met in this point)
    -Complete resection (or as complete as possible) of all Ta/T1 papillary disease prior to randomization, with the most recent TURBT occurring 2 months or less prior to signing informed consent for this study. Patients with residual CIS after TURBT are eligible.
    -No prior radiotherapy to the bladder.
    -No prior exposure to immune-mediated therapy of cancer including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 antibodies. Patients who have been treated with anticancer vaccines will be excluded.
    •BCG naïve (pacientes que no han recibido BCG intravesical previamente o que recibieron BCG, pero dejaron de hacerlo más de tres años antes de entrar en el estudio, pueden participar en el estudio).
    •Confirmación histológica local (basada en un informe patológico) de carcinoma celular transicional de urotelio de la vejiga urinaria confinado en la mucosa o submucosa de alto riesgo. Un tumor de alto riesgo se define como uno de los siguientes:
    -Tumor T1
    -Tumor alto grado/G3
    -CIS
    -Tumores múltiples, extensos (con un diámetro evaluable en el nodo más extenso ≥ 3 cm) y recurrentes (todas las condiciones deben cumplirse en este punto).
    •Resección completa (o tan completa como sea posible) de toda la enfermedad papilar Ta / T1 antes de la aleatorización, habiendo tenido lugar la resección transuretral de tumor vesical (RTU) 2 meses (o menos) antes de la firma del consentimiento informado para este estudio. Los pacientes con CIS residual después de RTU pueden participar en el estudio.
    •Sin radioterapia previa en la vejiga.
    •Sin exposición previa a la terapia de cáncer inmunomediada, que incluye, entre otros, anticuerpos anti-CTLA-4, anti-PD-1, anti-PD-L1 y anti células de muerte programadas ligadas a dos anticuerpos. Los pacientes que han sido tratados con vacunas contra el cáncer serán excluidos.
    E.4Principal exclusion criteria
    -Evidence of muscle-invasive, locally advanced, metastatic, and/or extra vesical bladder cancer (ie, T2, T3, T4, and / or stage IV).
    -Concurrent extravesical (ie, urethra, ureter, or renal pelvis), non-muscle-invasive transitional cell carcinoma of the urothelium.
    -Previous investigational product (IP) assignment in the present study.
    -Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for noncancer related conditions (eg, hormone replacement therapy) is acceptable.
    -Active infection including TB (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (HIV [positive HIV] 1/2) antibodies. Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody and absence of HBsAg) are eligible. Patients positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
    -Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:
     Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection)
     Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
     Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
    -15. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves’ disease, rheumatoid arthritis, hypophysitis, uveitis, etc]).
    -History of another primary malignancy
    •Evidencia de cáncer de vejiga y/o extra vesical metastásico, localmente avanzado, musculo invasivo (por ejemplo, T2, T3, T4 o estadio IV).
    •Carcinoma urotelial de células de transición, no invasivo de la muscular, extravesical concurrente(por ejemplo, uretra, uréter o pelvis renal)
    •Asignación previa del producto en investigación (IP) en el estudio actual
    •Cualquier quimioterapia concurrente, IP, terapia biológica u hormonal para el tratamiento del cáncer. Uso concurrente de terapia hormonal para enfermedades no relacionadas con el cáncer (por ejemplo, terapia de sustitución hormonal) es aceptable.
    • Infección activa incluyendo TB (evaluación clínica que incluye historia clínica, examinación física y hallazgos radiológicos, y pruebas de TB de acuerdo con la practica local), hepatitis B (conocimiento de resultado positivo del antígeno de superficie [HBsAg] del virus de la hepatitis B [HBV]), virus de la hepatitis C (HCV), o virus de la inmunodeficiencia humana (HIV [positivo HIV] 1/2) anticuerpos. Pacientes que han pasado o se han curado de una infección de HBV (definido como la presencia del anticuerpo core de la hepatitis B y la ausencia de HBsAG) pueden participar en el estudio. Pacientes positivos para el anticuerpo de la hepatitis C pueden participar en el estudio solo si la reacción de la cadena de la polimerasa es negativa para el ácido ribonucleico (RNA) de la HCV
    •Uso actual o anterior de medicación inmunosupresora dentro de los 14 dias antes de la primera dosis de durvalumab. Las excepciones para este criterio son las siguientes:
    -Esteroides tópicos, inhalados o intranasales o inyecciones de esteroides locales (e.j., inyección intraarticular)
    -Corticosteroides sistémicos a dosis fisiológicas que no excedan los 10mg/día de la prednisona o su equivalente
    -Esteroides como premedicación para las reacciones hipersensibles (e.j, premedicación para el escáner tomográfico computarizado)
    •Enfermedades inflamatorias o auntoinmunes previas o activas incluyendo la enfermadad de instentino inflamado (e.j. colitis o enferemedad de Chron) diverticulitis [con la excepción de diverticulosis], eritema lupus sistematico, síndrome sarcoidosis o sindrome Wegener [granulomatosis con poliangitis, enfermedad de Graves, artritis reumatoide, hipofisitis, uveítis, etc]).
    •Antecedente de alguna otra malignidad primaria
    E.5 End points
    E.5.1Primary end point(s)
    Disease-free survival (DFS)
    Supervivencia sin enfermedad (SSE)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Patients will be assessed by investigator tumor assessments every 3 months relative to the date of randomization until month 36, and then every 6 months according to standard of care or until disease progression.
    Todos los pacientes serán evaluados por las evaluaciones del tumor por el investigador cada 3 meses en relación con la fecha de aleatorización hasta 36 meses, y después cada 6 meses según los estándares de tratamiento o hasta la progresión de la enfermedad.
    E.5.2Secondary end point(s)
    Disease free at 24 months (DFS24)

    Survival at 5 years (OS5)

    Any disease-free survival (aDFS)

    Time to muscle-invasive bladder (MIC) cancer or metastasis

    Time to cystectomy.

    Time to development of upper track urothelial carcinoma (UTUC)

    Disease related symptoms

    Patient reported treatment tolerability

    Assessment of PK of Durvalumab

    Immunogenicity of Durvalumab (ADA) in combination with BCG
    Supervivencia libre de enfermedad a los 24 meses (SLE24).

    Supervivencia global a los 5 años (SG5).

    Toda supervivencia sin enfermedad (aSSE)

    Tiempo transcurrido hasta la aparición de cáncer de vejiga músculo no invasivo (CVIM) o metástasis.

    Tiempo transcurrido hasta la cistectomía.

    Tiempo transcurrido hasta la aparición de carcinoma urotelial de las vías superiores (CU-VUS).

    Síntomas relacionados con la enfermedad.

    Tolerabilidad del tratamiento notificada por el paciente.

    Evaluación de la farmacocinética de durvalumab.

    Inmunogenicidad de durvalumab (AAF) en combinación con BCG.
    E.5.2.1Timepoint(s) of evaluation of this end point
    DFS24,OS5, aDFS, Time to MIC, metastasis, cystectomy and UTUC will be assessed by disease assessments every 3 months until month 36 and then every 6 months.
    Disease related symptoms will be assessed with EORTC QLQ-C30 and EORTC QLQ NMIBC24 questionnaires. They should be completed at the first week of treatment and every 4 and 8 weeks until the end of the disease assessment period.
    Patient reported treatment tolerability will be assessed by PRO-CTCAE questionnaires every 4 weeks until the end of the disease assessment period.
    Concentration of Durvalumab (PK) will be assessed 5 times: pre- dose and post- dose for week 1, pre-dose at week 5 and week 25 and at week 12 of the follow-up period.
    ADA and nAB will be assessed 4 times: week 1, week 5, week 25 and week 12 of follow-up period.
    SLE24,SG5,aSSE, tº CVIM o metástasis, cistectomía y CU-VUS serán evaluados por evaluaciones de la enfermedad cada 3m hasta el mes 36 y después cada 6m. Síntomas relacionados con la enfermedad serán evaluados con QLQ-LC30 de la EORTC y QLQ-NMIBC24 de la EORTC. Deben ser completados en la 1ª sem de tto y cada 4 y 8 sem hasta que termine el periodo de evaluación de la enfermedad. La tolerabilidad del tto notificada por el paciente será evaluada por PRO-CTCAE cada 4 sem hasta que termine el periodo de evaluación de la enfermedad. La concentración de durvalumab (PK) será evaluada 5 veces: pre y pos-dosis para la sem1, pre-dosis en la sem 5 y 25 y en la sem 12 del periodo de seguimiento. AAF y nAB serán evaluados 4 veces: sem 1,5,25 y sem 12 después del periodo de seguimiento.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Quality of Life
    Health Care resource utilization
    Tolerability
    Calidad de vida
    Utilización de recursos de atención médica
    Tolerabilidad
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    BCG (Bacillus Calmatte-Guerin) solución intravesical
    BCG (Bacillus Calmatte-Guerin) intravesical solution
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned11
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA50
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Germany
    Japan
    Poland
    Russian Federation
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    LSLV
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 292
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 683
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state200
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 415
    F.4.2.2In the whole clinical trial 975
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Niguna
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-06-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2018-05-30
    P. End of Trial
    P.End of Trial StatusRestarted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA